Sex hormones and related compounds, including hormonal contraceptives
| Autor: | M.N.G. Dukes |
|---|---|
| Rok vydání: | 2008 |
| Předmět: | |
| Zdroj: | Side Effects of Drugs Annual ISBN: 9780444527677 Side Effects of Drugs Annual ISBN: 9780444506740 Side Effects of Drugs Annual ISBN: 9780444513564 |
| DOI: | 10.1016/s0378-6080(08)00040-8 |
| Popis: | Publisher Summary This chapter elaborates the sex hormones and related compounds, including hormonal contraceptives. In a multicenter, double-blind, placebo-controlled study, 152 hysterectomized healthy postmenopausal women were randomized to receive daily transdermal 17β-estradiol or oral micronized 17β-estradiol for thirteen 28-day treatment cycles, to compare the effects of the forms of administration on asymmetrical dimethylarginine, an endogenous inhibitor of nitric oxide synthase. In seven postmenopausal women who used vaginal estrogens while taking aromatase inhibitors for breast cancer, serum estradiol concentrations rose from baseline concentrations of below 5 pmol/l, consistent with aromatase inhibitor therapy, to a mean of 72 pmol/l at 2 weeks and by 4 weeks this had fallen to the pretreatment concentration. The risks of esophageal atresia/tracheoesophageal fistula in the children of mothers who had been exposed in utero to diethylstilbestrol have been studied. In a comparison of postmenopausal women after myocardial infarction or stroke with 4,205 controls, there was no difference in the risk of myocardial infarction or stroke associated with current use of conjugated equine estrogens or esterified estrogens compared with no treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|